Australia switches chloramphenicol eye drops
This article was originally published in The Tan Sheet
Executive SummaryAustralia moves chloramphenicol-containing eye drops to nonprescription distribution by pharmacists, harmonizing the country's regulation with New Zealand's. The National Drugs and Poisons Schedule Committee in October said that other nonprescription products are indicated for mild cases of bacterial conjunctivitis, but it is "sensible to allow pharmacists to supply cholramphenicol for the treatment of more severe, uncomplicated cases." Australia and New Zealand are harmonizing requirements for therapeutic products and establishing a joint regulatory scheme under the Trans-Tasman Mutual Recognition Arrangement (1"The Tan Sheet" Feb. 2, 2009). Chloramphenicol-containing eye drops remain Rx in the U.S
You may also be interested in...
UK pharma announced that in 2021 it will close its manufacturing facility in Carlisle, PA, where around 260 people are employed making the Emergen-C line. It will move the manufacturing to its Guayama, PR, facility.
Unless reauthorized by Congress, the rare pediatric disease program will begin to expire in September; renewal could bring bigger changes across the three PRV programs, including an FDA-requested clarification of biologic products eligible for vouchers and reforms suggested by sponsors and other stakeholders in a recent GAO report.